Unseen Upside: Investments Beyond Their Returns

How will evolving digital technologies impact healthcare delivery, patient experience, and access to care?According to new venture-backed companies, they can advance health equity, democratize access, and empower individuals to take control of their health journey. Alongside industry pioneers and investors, we explore digital health advancements such as telemedicine, remote monitoring, and data-driven diagnostics that are all working to improve healthcare efficiencies.Join us as we uncover the potential of these technologies to improve healthcare outcomes for all.Guests include: Lynne Chou O'Keefe, Founder & Managing Partner at Define Ventures Siva Namasivayam, CEO & Co-Founder at Cohere Health Chavon Sutton, Senior Investment Director in the Sustainable & Impact Investing Research Group at Cambridge AssociatesUnseen Upside: Investments Beyond Their Returns is developed in partnership with PRX, an award-winning podcast media company.Cambridge Associates is a global investment firm that works with endowments, foundations, healthcare systems, pension plans, and private clients to implement and manage custom investment portfolios that aim to generate outperformance and maximize their impact on the world. Cambridge Associates delivers a range of portfolio management services, including outsourced CIO, non-discretionary portfolio management, staff extension, and asset class mandates.

Join us in Kotzebue, Alaska to explore the issue of rural healthcare and the inequities faced by these communities.We shine a light on innovative solutions aimed at improving rural healthcare delivery, like a program called Siamit that’s connecting cutting-edge medicine from Massachusetts General Hospital (MGH) and Harvard Medical School to the tribal regions of Alaska. We also look at the role of venture capital in driving advancements that promote access to healthcare for those living in rural parts of the country.Guests include: Lucas Trout, Lecturer on Global Health and Social Medicine at Harvard Medical School Susan Rawlings Molina, Co-Founder and CEO at GroundGame Health Alyssa Jaffee, Partner at 7wireVenturesUnseen Upside: Investments Beyond Their Returns is developed in partnership with PRX, an award-winning podcast media company.Cambridge Associates is a global investment firm that works with endowments, foundations, healthcare systems, pension plans, and private clients to implement and manage custom investment portfolios that aim to generate outperformance and maximize their impact on the world. Cambridge Associates delivers a range of portfolio management services, including outsourced CIO, non-discretionary portfolio management, staff extension, and asset class mandates.

Prescription drug prices in the United States are 2.78 times higher than in other developed countries, but why?We untangle the barriers surrounding drug affordability and find out why accessing life-saving medications is costly to so many. Joined by experts, advocates, and one Cystic Fibrosis patient relying on expensive medication to live, we examine the complex factors contributing to the high costs of drugs, from research and development to pricing strategies and supply chain dynamics. We also investigate potential solutions to improve access and affordability without compromising on drug innovation.Guests include: Peter Kolchinsky, Founder and Managing Partner at RA Capital Gunnar Esiason, Head of Patient Engagement at RAVen (RA Ventures) Dean Dimizas, Partner in the Private Client Practice at Cambridge AssociatesUnseen Upside: Investments Beyond Their Returns is developed in partnership with PRX, an award-winning podcast media company.Cambridge Associates is a global investment firm that works with endowments, foundations, healthcare systems, pension plans, and private clients to implement and manage custom investment portfolios that aim to generate outperformance and maximize their impact on the world. Cambridge Associates delivers a range of portfolio management services, including outsourced CIO, non-discretionary portfolio management, staff extension, and asset class mandates.

Join us as we head to the Bronx to examine the critical intersection of housing and health and the innovative solutions that are aiming to address the affordable housing crisis in major cities like New York and LA. Through conversations with non-profit leaders and impact investors, we dive into how affordable housing impacts public health and health equity, highlighting the investment strategies and community partnerships that are moving the needle. We also discuss the challenges of housing insecurity and the disproportionate effects on marginalized communities, recognizing affordable housing is a critical determinant of community health. Guests include: Margaret Anadu, Senior Partner at The Vistria Group Tim Ortez, Vice President & Chief Financial Officer at Weingart Foundation Jasmine Richards, Head of Diverse Manager Research at Cambridge AssociatesUnseen Upside: Investments Beyond Their Returns is developed in partnership with PRX, an award-winning podcast media company. Cambridge Associates is a global investment firm that works with endowments, foundations, healthcare systems, pension plans, and private clients to implement and manage custom investment portfolios that aim to generate outperformance and maximize their impact on the world. Cambridge Associates delivers a range of portfolio management services, including outsourced CIO, non-discretionary portfolio management, staff extension, and asset class mandates.

How does venture capital contribute to advancing health equity and public health? Find out on season five of Unseen Upside, premiering Tuesday, October 8.This season, we dive into how today's investment decisions are shaping tomorrow's innovations in critical areas such as affordable housing, maternal health, drug pricing, and more. Join us for engaging conversations with investors and entrepreneurs as we uncover the profound impact of venture capital on our lives on a grand scale.Powered by the global network of Cambridge Associates, join us to explore healthcare investments beyond their returns.Listen now to Unseen Upside.

While we’re busy pulling together stories for the fifth season of Unseen Upside, we thought you might be curious about what it is that Cambridge Associates actually does. In a nutshell, we have the privilege of partnering with some of the world’s top institutional investors—like nonprofits, universities, hospitals, pension plans, and even private families—and we try to help them reach their investment goals.Recently, we had a conversation with four of our non-profit clients from institutions with assets ranging from $200 million to $850 million to understand why they chose to outsource day-to-day portfolio decisions so they could focus on bigger picture strategy for their organizations. Their stories offer insight into how we collaborate with clients so they can do even more for the communities they serve. Don’t forget to check back this fall for the latest season of Unseen Upside: Investments Beyond Their Returns.Unseen Upside: Investments Beyond Their Returns is developed in partnership with PRX, an award-winning podcast media company. Cambridge Associates is a global investment firm that works with endowments, foundations, healthcare systems, pension plans, and private clients to implement and manage custom investment portfolios that aim to generate outperformance and maximize their impact on the world. Cambridge Associates delivers a range of portfolio management services, including outsourced CIO, non-discretionary portfolio management, staff extension, and asset class mandates.

Artificial intelligence is transforming healthcare, unleashing new investment opportunities. From cancer screening to drug discovery, AI promises to augment clinical decision-making and improve care. We’ll explore the surging ecosystem of medical AI innovations, from the emerging tech landscape to practical deployment. But what are the challenges facing real-world implementation? Which applications show the most promise? Join us as we investigate how artificial intelligence can change healthcare for the better while examining what it will take to do it well. Guests include: Bob Nelsen, Co-Founder and Managing Director at Arch Venture Partners Daphne Koller, Founder and CEO at insitro David Baker, Ph.D., 2024 Nobel Prize in Chemistry Laureate, Director at the Institute for Protein Design and Professor of Biochemistry at University of Washington Theresa Hajer, Partner and Managing Director of Venture Capital Research at Cambridge AssociatesUnseen Upside: Investments Beyond Their Returns is developed in partnership with PRX, an award-winning podcast media company. Cambridge Associates is a global investment firm that works with endowments, foundations, healthcare systems, pension plans, and private clients to implement and manage custom investment portfolios that aim to generate outperformance and maximize their impact on the world. Cambridge Associates delivers a range of portfolio management services, including outsourced CIO, non-discretionary portfolio management, staff extension, and asset class mandates.

Autoimmune diseases like lupus impact over 5 million patients globally, but treatment options remain limited. Now, decoding the once mysterious "dark genome" could bring new therapies. Over 90% of our DNA was once considered "junk"—but we’ve learned this dark matter regulates gene expression and human disease. This episode takes you to the pioneers who are unlocking the dark genome's potential to correct root causes of complex conditions like lupus. We'll chat with those illuminating this uncharted territory and developing novel approaches. Guests include: Rosana Kapeller, M.D., Ph.D., Co-Founder, President, & CEO at Rome Therapeutics Steve Kafka, General Partner at S32 Keri Mastrogiacomo, mother of a Lupus patient Katherine Cavanagh, Associate Investment Director at Cambridge Associates This episode has named a Winner by the International Women’s Podcast Awards for their “A Moment of Visionary Leadership” category.Unseen Upside: Investments Beyond Their Returns is developed in partnership with PRX, an award-winning podcast media company. Cambridge Associates is a global investment firm that works with endowments, foundations, healthcare systems, pension plans, and private clients to implement and manage custom investment portfolios that aim to generate outperformance and maximize their impact on the world. Cambridge Associates delivers a range of portfolio management services, including outsourced CIO, non-discretionary portfolio management, staff extension, and asset class mandates.

Obesity is a global health crisis, with over 650 million adults affected worldwide. This drives massive economic and disease burdens. Yet new treatment options like GLP-1 drugs offer hope. This episode analyzes the investment landscape and future of obesity therapeutics, focusing on transformational GLP-1 drugs like Ozempic that curb appetite. Join us as we investigate the promise and challenges of emerging anti-obesity drugs, learn about one patient’s journey taking them, and discover what the future of weight loss medicine could look like. You'll hear from leaders in the space as well as a current patient taking these medications. Guests include: Rod Wong, Founder, Managing Partner, and Chief Investment Officer at RTW Investments Raymond Stevens, Ph.D., Chief Executive Officer at Structure Therapeutics Dean Dimizas, Partner and Managing Director at Cambridge Associates Kathleen Mikaelian, PatientUnseen Upside: Investments Beyond Their Returns is developed in partnership with PRX, an award-winning podcast media company. Cambridge Associates is a global investment firm that works with endowments, foundations, healthcare systems, pension plans, and private clients to implement and manage custom investment portfolios that aim to generate outperformance and maximize their impact on the world. Cambridge Associates delivers a range of portfolio management services, including outsourced CIO, non-discretionary portfolio management, staff extension, and asset class mandates.

Precision oncology represents an exciting shift in cancer treatment from a one-size-fits-all approach to personalized care based on each patient's unique cancer and molecular makeup. In this episode, we'll explore how precision oncology is transforming the landscape of cancer care and improving outcomes at leading hospitals like St. Jude Children’s Research Hospital. We'll discuss the latest precision diagnostic technologies enabling doctors to analyze a tumor's molecular profile and match targeted therapies to save lives. Join us as we investigate the promise of precision medicine to make cancer treatment more effective and more equitable. Guests include: Rick Shadyac, President and CEO at ALSAC, the fundraising and awareness organization for St. Jude Children’s Research Hospital, a Cambridge Associates client Matt Gevaert, Co-Founder and Board Member at Kiyatec Jason Robart, Co-Founder & Managing Partner at Seae Ventures Jeff Blazek, Partner and Head of the Northeast & Midwest Endowment & Foundation Practice at Cambridge Associates, who works with ALSAC/St. Jude as one of his clients, in partnership with Anurag Pandit, CIO of ALSAC/SJCRH, and the Investment Department.Unseen Upside: Investments Beyond Their Returns is developed in partnership with PRX, an award-winning podcast media company. Cambridge Associates is a global investment firm that works with endowments, foundations, healthcare systems, pension plans, and private clients to implement and manage custom investment portfolios that aim to generate outperformance and maximize their impact on the world. Cambridge Associates delivers a range of portfolio management services, including outsourced CIO, non-discretionary portfolio management, staff extension, and asset class mandates.

Thanks to medical advances, we're living longer lives but with that comes rising rates of Alzheimer's disease. Currently 6 million Americans have Alzheimer's, and that could triple by 2050. This episode explores emerging innovations offering hope against neurodegenerative diseases. We'll discuss promising new drugs that could slow cognitive decline and the strides scientists are making towards understanding causes and developing therapies—and how these breakthroughs are giving hope to one family fighting to save their mom. Episode two explores the history of Alzheimer’s, its current challenges, and the promising therapies made possible by innovation and investment. You’ll hear from: Dr. Asa Abeliovich, Neurologist, Molecular Geneticist, and Founder and CEO at Leal Therapeutics Carl Gordon, Managing Partner and Head of Global Private Equity at OrbiMed Ham Lee, Co-Head of the Healthcare Practice at Cambridge Associates Randi Casciano, Director of Global Public Relations at Cambridge AssociatesUnseen Upside: Investments Beyond Their Returns is developed in partnership with PRX, an award-winning podcast media company. Cambridge Associates is a global investment firm that works with endowments, foundations, healthcare systems, pension plans, and private clients to implement and manage custom investment portfolios that aim to generate outperformance and maximize their impact on the world. Cambridge Associates delivers a range of portfolio management services, including outsourced CIO, non-discretionary portfolio management, staff extension, and asset class mandates.

The mental health crisis is growing, especially among Gen Z (91% report anxiety or depression). This episode explores innovations in mental healthcare access, new therapeutic approaches for young people and families, and how hospitals are striking creative partnerships to tackle this emergency. Tune in to learn what’s working and showing promise in mental healthcare, glimpses of what the future could look like, and where persistent gaps remain. Hear from leaders Melody Dickerson (VHC Health); Emily Melton (Threshold Ventures); Naomi Allen (Brightline); and Bridget Sproles (Cambridge Associates).

The future of healthcare is here. Get an an inside look at the innovations transforming lives on season four of Unseen Upside, premiering Tuesday, February 6. This season, we pull back the curtain on cutting-edge advancements at the intersection of technology and medicine, learn how AI is revolutionizing diagnostics and treatment, discover the potential of GLP-1s to combat obesity, and how breakthrough Alzheimer's therapies are offering hope to millions. We'll also uncover creative approaches to solving the mental health crisis. Powered by the global network of Cambridge Associates, join us to explore healthcare investments beyond their returns.

The fashion industry accounts for up to 10% of global carbon dioxide output and roughly 2.6 million tons of clothing returns end up in US­­­ landfills each year instead of being resold. Meanwhile, the shipping for these returns account for around 16 million tons of CO2 emissions—and fast fashion is making things worse. But what if deep tech could help to cut down on returns? Amid the rise of conscious consumerism, one company is using video game technology and AI generated avatars to help online shoppers try on clothing virtually before they buy, in the hopes of making the fashion industry more sustainable. We’ll learn more from Christine Marzano (BODS); Carle Stenmark (VMG Partners); Jennifer Varekamp (MassArt); and Annachiara Marcandalli (Cambridge Associates).

More than two-thirds of our electricity is generated by burning fossil fuels, a major climate change contributor. As such, use of renewable energy is expected to double in the next 15 years. But there’s a catch: the power they generate depends on variable factors like wind and sun, making them too unreliable to power our grid. However, recent battery innovations could be the solution. One company has developed an iron-air battery capable of storing energy for multiple days, which may be the missing link needed to decarbonize our grid for good. Join us to learn more from Mateo Jaramillo and Jocelyn Newhouse (Form Energy); Dipender Saluja (Capricorn Investment Group); Anders Lyngaa Kristoffersen (The Velux Foundations); and Di Tang (Cambridge Associates).

Humans have fantasized about flying cars for decades, but they’ve yet to leave the pages of our sci-fi books...or have they? Join us as we visit Joby Aviation out in Marina, California to witness their eVTOL (electric vertical take-off and landing) aircraft take flight. With plans to operate like ubers in the sky, eVTOLs are the closest thing we have to flying cars—and they could be a commercial reality by 2025. The companies creating them promise a faster and greener mode of transportation, but who’s investing in them? Are they safe? And how will they change our transportation infrastructure? We’ll discuss these questions and more with Eric Allison (Joby Aviation); Andrew Beebe (Obvious Ventures); and Doug Carlson and Alex Innes-Whitehouse (pilots affiliated with Cambridge Associates).

According to scientists, 30,000 species per year are being driven towards extinction and 50% of all species could be extinct by 2050 due to climate change. But what if there was something we could do, in addition to conservation, to change this trajectory? That’s what the scientists and engineers at Colossal Biosciences are working towards: reversing extinction. Using CRISPR and advanced gene editing techniques, they plan to bring back the woolly mammoth and the dodo bird to help combat climate change and complement existing conservation efforts. Join us to discuss this topic with Ben Lamm (Colossal Biosciences); Tom Chi (At One Ventures); and John Calvelli (Wildlife Conservation Society).

Harnessing fusion power has been an elusive goal of physicists and researchers for decades. However, recent scientific advances are helping to make that goal a reality. Described as a star in a bottle, fusion is what powers our sun and stars, offering us the prospect of limitless clean energy. But here on earth, it has presented unresolved engineering challenges—until now. Commonwealth Fusion Systems is on the brink of delivering commercial fusion energy thanks to their revolutionary magnet. But how does a safe, limitless, carbon-free, fusion power plant operate? What does it look like? How and when will this technology be replicated to meet the world’s energy needs? We’ll learn more from Bob Mumgaard (Commonwealth Fusion Systems); Katie Rae (The Engine); and Theresa Hajer (Cambridge Associates).

Season three of Unseen Upside: Investments Beyond Their Returns by Cambridge Associates explores the innovations turning science fiction to fact and the people investing in them. Powered by the global network of Cambridge Associates, discover the investments being made that will redefine our future. Join us to uncover the Unseen Upside.

We’ve all dreamt of traveling to outer space and recently, that dream has been more tangible than ever. But for those of us without a seat on the next rocket, how will space innovation improve our lives here on Earth? It turns out that the microgravity environment of orbit provides manufacturing capabilities that aren’t possible on earth. It allows us to create things—think artificial organs, life-saving pharmaceuticals, fiber optic cables, and other products—that are superior to those created on our planet. In this episode, we explore the growing Space Economy with Delian Asparouhov (Varda/Founders Fund); Tess Hatch (Bessemer Venture Partners); Alex Readey (Cambridge Associates); and a seven-year-old aspiring astronaut.